Q4 2024 FINANCIAL RESULTS FEBRUARY 10, 2025 FORWARD LOOKING STATEMENTS & NON-GAAP FINANCIAL MEASURES Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this presentation that do not relate to matters of historical fact should be considered forward- looking statements, including without limitation, statements regarding our forecasted financial results and the effective tax rat ...

Company Performance - Medpace reported quarterly earnings of $3.67 per share, exceeding the Zacks Consensus Estimate of $2.97 per share, and up from $2.46 per share a year ago, representing an earnings surprise of 23.57% [1] - The company posted revenues of $536.59 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 0.04%, and an increase from $498.4 million year-over-year [2] - Over the last four quarters, Medpace has surpassed consensus EPS estimates four times, but has only topped consensus revenue estimates once [2] Stock Outlook - Medpace shares have increased approximately 6.6% since the beginning of the year, outperforming the S&P 500's gain of 2.5% [3] - The current consensus EPS estimate for the upcoming quarter is $2.95 on revenues of $539.1 million, and for the current fiscal year, it is $12.42 on revenues of $2.21 billion [7] - The estimate revisions trend for Medpace is currently favorable, leading to a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - The Medical Services industry, to which Medpace belongs, is currently ranked in the bottom 33% of over 250 Zacks industries, suggesting potential challenges ahead [8] - The performance of Medpace's stock may be influenced by the overall outlook for the industry, as research indicates that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8]

Revenue Performance - Revenue for Q4 2024 increased 7.7% to $536.6 million compared to $498.4 million in Q4 2023, with a backlog conversion rate of 18.3%[3][8] - Full year 2024 revenue increased 11.8% to $2,109.1 million from $1,885.8 million in 2023[10] - Revenue for Q4 2024 was $536.6 million, an increase of 7.7% from $498.4 million in Q4 2023[30] Business Awards and Book-to-Bill Ratio - Net new business awards for Q4 2024 were $529.7 million, a decrease of 13.8% from $614.7 million in Q4 2023, resulting in a net book-to-bill ratio of 0.99x[4][8] - For the full year 2024, net new business awards totaled $2,230.0 million, with a net book-to-bill ratio of 1.06x, down from $2,356.7 million in 2023[11] Net Income and Earnings Per Share - GAAP net income for Q4 2024 was $117.0 million, or $3.67 per diluted share, compared to $78.3 million, or $2.46 per diluted share in Q4 2023, with a net income margin of 21.8%[6][8] - GAAP net income for the full year 2024 was $404.4 million, or $12.63 per diluted share, compared to $282.8 million, or $8.88 per diluted share in 2023, resulting in a net income margin of 19.2%[12] EBITDA Performance - EBITDA for Q4 2024 increased 39.3% to $133.5 million, representing 24.9% of revenue, compared to $95.8 million, or 19.2% of revenue in Q4 2023[7][8] - EBITDA for the full year 2024 increased 32.5% to $480.2 million, or 22.8% of revenue, compared to $362.5 million, or 19.2% of revenue in 2023[13] - EBITDA for Q4 2024 was $133.5 million, representing an EBITDA margin of 24.9%, compared to 19.2% in Q4 2023[34] Cash Flow and Liquidity - The company had cash and cash equivalents of $669.4 million as of December 31, 2024, and generated $190.7 million in cash flow from operating activities during Q4 2024[14] - Cash and cash equivalents rose significantly to $669.4 million in 2024, compared to $245.4 million in 2023, marking an increase of 172.5%[33] Guidance and Forecast - The company forecasts 2025 revenue between $2.110 billion and $2.210 billion, representing growth of 0.0% to 4.8% over 2024 revenue[16] - The company provided FY 2025 guidance for net income between $378.0 million and $402.0 million, with diluted earnings per share projected between $11.93 and $12.69[35] Operating Expenses and Liabilities - Operating expenses for Q4 2024 totaled $411.2 million, slightly up from $411.1 million in Q4 2023[30] - Total liabilities increased to $1.3 billion in 2024, compared to $1.1 billion in 2023, reflecting a growth of 16.2%[32] Assets and Advanced Billings - Total assets increased to $2.1 billion as of December 31, 2024, from $1.7 billion in 2023, reflecting a growth of 26.7%[32] - Advanced billings increased to $710.6 million in 2024, compared to $559.9 million in 2023, indicating a growth of 26.9%[32] Net Income Margin - The company reported a net income margin of 21.8% for Q4 2024, up from 15.7% in Q4 2023[34]

Group 1 - The core viewpoint of the article is a buy rating for Medpace Holdings (NASDAQ: MEDP) based on its strong financial performance [1] - Medpace Holdings has experienced a significant revenue growth of 123.65% from 2020 to Q3 2024 [1] Group 2 - The analyst, Daniel Mellado, has a background in economics and statistics, with experience in analyzing agricultural commodities and managing trading and data analysis teams [1] - Mellado's expertise includes developing strategies for algorithmic trading and providing analysis and valuation for sectors such as commodities, banking, technology, and pharmaceuticals [1]

Group 1 - Medpace Holdings, Inc. is currently under investigation for securities fraud, which raises concerns among investors [1] - Affected investors are encouraged to contact the Schall Law Firm for potential legal action [1]

Core Viewpoint - The Schall Law Firm is inviting shareholders who have incurred losses to participate in an inquiry regarding potential securities law violations by Medpace Holdings, Inc. [1] Group 1 - The inquiry is focused on possible violations of securities laws that may have affected shareholders [1] - Shareholders are encouraged to join the investigation if they have experienced financial losses related to Medpace Holdings, Inc. [1] - The law firm aims to determine whether the company engaged in any unlawful practices that could have impacted its stock performance [1]

Analyst Estimates and Stock Performance - Positive estimate revisions for Medpace indicate optimism about the company's business outlook [1] - Empirical research shows a direct correlation between estimate revisions and impending stock price performance [2] - Medpace currently holds a Zacks Rank of 2 (Buy), with stocks at 1 delivering an average annual return of +25% since 1988 [3] - The consensus EPS projection for Medpace has increased by 0.81% in the past 30 days [3] Valuation Metrics - Medpace trades at a PEG ratio of 1.8, higher than the industry average of 1.41 [4] - The company's Forward P/E ratio is 28.25, representing a premium compared to the industry average of 17.02 [8] Industry and Sector Performance - The Medical Services industry, part of the Medical sector, has a Zacks Industry Rank of 154, placing it in the bottom 39% of over 250 industries [4] - The top 50% rated industries outperform the bottom half by a factor of 2 to 1 [5] Recent Stock Performance - Medpace's stock closed at $352.01, marking a +0.32% move from the prior day, outperforming the S&P 500's daily gain of 0.16% [6] - Over the past month, Medpace shares gained 1.43%, while the Medical sector lost 5.3% and the S&P 500 lost 2.2% [6] Upcoming Earnings Release - Medpace plans to announce its earnings on February 10, 2025, with projected earnings of $2.97 per share, representing year-over-year growth of 20.73% [7] - The latest consensus estimate predicts revenue of $536.37 million, indicating a 7.62% increase compared to the same quarter of the previous year [7]

The latest trading session saw Medpace (MEDP) ending at $346.81, denoting a +1.39% adjustment from its last day's close. This move outpaced the S&P 500's daily loss of 1.11%. On the other hand, the Dow registered a loss of 0.42%, and the technology-centric Nasdaq decreased by 1.89%.The provider of outsourced clinical development services's stock has dropped by 2.88% in the past month, exceeding the Medical sector's loss of 6.22% and lagging the S&P 500's loss of 1.7%.Market participants will be closely foll ...

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Medpace (MEDP) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out.Medpace is one of 1020 companies in the Medical group. The Medical group currently sits at #2 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the stre ...

In the latest trading session, Medpace (MEDP) closed at $339.05, marking a +0.52% move from the previous day. The stock trailed the S&P 500, which registered a daily gain of 0.73%. Meanwhile, the Dow gained 0.16%, and the Nasdaq, a tech-heavy index, added 0.98%.Coming into today, shares of the provider of outsourced clinical development services had lost 0.14% in the past month. In that same time, the Medical sector lost 3.8%, while the S&P 500 gained 0.34%.The investment community will be closely monitorin ...